Vivek Ramaswamy

Founder & CEO

Our mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity.

We develop transformative medicines faster by building technologies and developing talent in creative ways.


We do that by leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies.


We have unique principles that shape our culture. We’re focused on creating value. We are contrarian. When we hit a wall, we climb the wall. We sweat the details. We accept that we must evolve or die.

ROIVANT OVERVIEW AT J.P. MORGAN HEALTHCARE CONFERENCE 2021
ROIVANT OVERVIEW AT J.P. MORGAN HEALTHCARE CONFERENCE 2021

The following companies are a part of Roivant's strategic alliance with Sumitomo Dainippon Pharma.

Pipeline

We have a diverse pipeline of investigational drugs across our family of companies.

Company
Compound
Indication
Therapeutic Area
Modality
Phase
Dermavant
Tapinarof
Psoriasis
Dermatology
Topical
Phase 3

Tapinarof is a potential first-in-class, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream being developed for the treatment of plaque psoriasis and atopic dermatitis. In August 2020, Dermavant announced positive results from PSOARING 1 and PSOARING 2, two identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream, 1% in adult patients with plaque psoriasis.

In both PSOARING 1 (N=510) and PSOARING 2 (N=515), tapinarof cream demonstrated highly statistically significant improvement in Physician Global Assessment (PGA) score of clear (0) or almost clear (1) with a minimum 2-grade improvement compared to vehicle from baseline at Week 12 (both P<0.0001), thus meeting the primary endpoint of each trial. In addition, all secondary endpoints were achieved in both trials, including PASI75. To date, over 2,200 subjects have enrolled in 17 clinical trials of tapinarof.

Learn more at dermavant.com

Sinovant
Lefamulin
Community-Acquired Pneumonia
Infectious Disease
Small Molecule
Phase 3

Sinovant is initially developing lefamulin for community-acquired pneumonia, one of the leading causes of mortality in Mainland China. Due to its novel mechanism of action, low incidence of cross-resistance between other antibacterial agents commonly used to treat community-acquired pneumonia, and low propensity for bacterial resistance to develop, lefamulin has the potential to be used as a first-line empiric monotherapy for the treatment of community-acquired pneumonia.

Lefamulin has successfully completed two global Phase 3 studies in patients with moderate and severe community-acquired pneumonia. Lefamulin has been granted Qualified Infectious Disease Product (QIDP) designation from the US FDA and is currently in preparation for an MAA in Europe.

In June 2019, the China National Medical Products Administration approved Sinovant’s Clinical Trial Application for lefamulin. In August 2019, Sinovant’s partner Nabriva Therapeutics received FDA approval of lefamulin to treat community-acquired bacterial pneumonia.

Learn more at sinovant.com

Sinovant
Derazantinib
Intrahepatic Cholangiocarcinoma
Oncology
Small Molecule
Phase 3

Sinovant is initially developing derazantinib, a potent, orally administered inhibitor of the fibroblast growth factor receptor (FGFR) family, for the treatment of intrahepatic cholangiocarcinoma (iCCA), a devastating form of biliary tract cancer with high incidence in Greater China and parts of Asia and no approved therapies. In a Phase 1/2 study in patients with iCCA harboring FGFR2 gene fusions, treatment with derazantinib resulted in an objective response rate of 21%, nearly 3 times higher than standard-of-care chemotherapy.

Derazantinib is currently being evaluated in a registration-enabling study in patients with FGFR2 fusion-positive second-line iCCA in the United States and Europe.

Learn more at sinovant.com

Aruvant
ARU-1801
Sickle Cell Disease
Hematology
Gene Therapy
Phase 2

ARU-1801 is an investigational gene therapy for sickle cell disease and β-thalassemia. ARU-1801 utilizes proprietary technology intended to increase functioning red blood cells by inserting a modified fetal hemoglobin gene into autologous stem cells through a lentiviral vector. Studies have indicated that sickle cell patients with elevated levels of fetal hemoglobin have fewer vaso-occlusive crises and hospitalizations.

Learn more at momentumtrials.com

Dermavant
Cerdulatinib
Vitiligo
Dermatology
Topical
Phase 2

Cerdulatinib is a topical dual janus kinase (JAK) and spleen tyrosine kinase (Syk) inhibitor. Dermavant is developing cerdulatinib as a topical therapy for a variety of dermatologic conditions. Dermavant believes that the profile of cerdulatinib is ideal for development in skin diseases where a growing body of evidence suggests that both JAK and Syk are important drivers of disease manifestation.

Learn more at dermavant.com

Dermavant
Tapinarof
Atopic Dermatitis
Dermatology
Topical
Phase 2

Tapinarof is a potential first-in-class, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream being developed for the treatment of plaque psoriasis and atopic dermatitis. In August 2020, Dermavant announced positive results from PSOARING 1 and PSOARING 2, two identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream, 1% in adult patients with plaque psoriasis.

In both PSOARING 1 (N=510) and PSOARING 2 (N=515), tapinarof cream demonstrated highly statistically significant improvement in Physician Global Assessment (PGA) score of clear (0) or almost clear (1) with a minimum 2-grade improvement compared to vehicle from baseline at Week 12 (both P<0.0001), thus meeting the primary endpoint of each trial. In addition, all secondary endpoints were achieved in both trials, including PASI75. To date, over 2,200 subjects have enrolled in 17 clinical trials of tapinarof.

Learn more at dermavant.com

Immunovant
IMVT-1401
Warm Autoimmune Hemolytic Anemia
Immunology
Biologic
Phase 2

Warm autoimmune hemolytic anemia (WAIHA) is a rare hematologic disease in which autoantibodies mediate hemolysis, or the destruction of red blood cells. WAIHA approximately affects 42,000 people in the United States and 66,000 people in Europe. The clinical presentation is variable and most commonly includes non-specific symptoms of anemia such as fatigue, weakness, skin paleness, and shortness of breath. Symptoms typically develop chronically over several weeks to months, but rapid progression over a span of days has also been observed.

Immunovant is developing IMVT-1401, a novel, fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (FcRn), for the treatment of immunoglobulin G (IgG) mediated diseases, such as WAIHA. IMVT-1401 is being developed as a subcutaneous injection, providing a convenient and minimally invasive treatment option for patients.

Learn more at immunovant.com

Immunovant
IMVT-1401
Myasthenia Gravis
Immunology
Biologic
Phase 2

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness and fatigue of voluntary muscles. Symptoms typically emerge in the eyes (e.g., drooping eyes, double-vision, blurred vision) and progress into the face, throat, and limbs. MG is a rare disease that affects approximately 65,000 people in the United States and 104,000 people in Europe, with a greater prevalence among younger women and older men.

The chronic nature of MG requires patients to cope with fluctuating symptoms and multiple treatment regimens for management. Persistent muscle weakness associated with MG often negatively interferes with patients’ ability to engage in daily and physical activities, including demands of work, family, and social functions.

Immunovant is developing IMVT-1401, a novel, fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (FcRn), for the treatment of immunoglobulin (IgG) mediated diseases, such as MG. IMVT-1401 is being developed as a subcutaneous injection, providing a convenient and minimally invasive treatment option for patients.

Learn more at immunovant.com

Immunovant
IMVT-1401
Thyroid Eye Disease
Immunology
Biologic
Phase 2

Thyroid eye disease (TED), also known as Graves’ ophthalmopathy, is an autoimmune disorder that affects the muscles and other tissues around the eyes. TED approximately affects 33,000 people in the United States and 52,000 people in Europe. Moderate-to-severe TED is characterized by swelling and redness of the eyelids, proptosis (protrusion of the eyeball), double vision, and, in severe cases, corneal ulceration and decreased visual acuity.

Immunovant is developing IMVT-1401, a novel, fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (FcRn), for the treatment of immunoglobulin (IgG) mediated diseases, such as TED. IMVT-1401 is being developed as a subcutaneous injection, providing a convenient and minimally invasive treatment option for patients.

Learn more at immunovant.com

Kinevant
Gimsilumab
COVID-19-Associated ARDS
Respiratory Disease
Biologic
Phase 2

COVID-19, an infectious disease caused by SARS-CoV-2, has become a global pandemic. Patients with severe cases of COVID-19 experience severe viral pneumonia that often persists despite a decrease in viral load, and can progress to ARDS and death. When implementing standard of care, including mechanical ventilation, ARDS has an overall mortality rate of 41%.

Roivant is developing gimsilumab, a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients with or at risk of developing ARDS. Gimsilumab has been tested in numerous non-clinical and two clinical studies for rheumatoid arthritis, including a 4-week Phase 1 study in healthy volunteers conducted by Roivant which completed dosing in February.

In April 2020, Roivant announced the dosing of the first patient in the BREATHE Phase 2 clinical trial of gimsilumab in COVID-19 patients for the prevention and treatment of ARDS.

For more information, click here.

Sio Gene Therapies
AXO-LENTI-PD
Parkinson's Disease
Neurology
Gene Therapy
Phase 2

AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes via a single lentiviral vector to encode a set of critical enzymes required for dopamine synthesis, with the goal of reducing variability and restoring steady levels of dopamine in the brain. The gene therapy aims to provide patient benefit for years following a single administration.

Learn more at https://siogtx.com/

Sio Gene Therapies
AXO-AAV-GM1
GM1 Gangliosidosis
Neurology
Gene Therapy
Phase 2

AXO-AAV-GM1 delivers a functional copy of the GLB1 gene via an adeno-associated viral (AAV) vector, AAV9, which is effective in crossing the blood-brain barrier and transducing neurons, with the goal of restoring β-gal enzyme activity for the treatment of GM1 gangliosidosis. The gene therapy is delivered intravenously, which has the potential to broadly transduce the central nervous system and treat peripheral manifestations of the disease.

In preclinical studies, AXO-AAV-GM1 was shown to improve β-gal enzyme activity, reduce GM1 ganglioside accumulation, improve neuromuscular function, and extend survival. Magnetic resonance imaging (MRI) of felines with GM1 gangliosidosis treated with AXO-AAV-GM1 showed normal brain architecture through at least two years of age.

Learn more at https://siogtx.com/

Sio Gene Therapies
AXO-AAV-GM2
Tay-Sachs/Sandhoff Disease
Neurology
Gene Therapy
Phase 2

AXO-AAV-GM2 delivers functional copies of the HEXA and HEXB genes via two, co-administered AAVrh8 vectors delivered directly to the central nervous system with the goal of restoring Hex A enzyme activity to address both Tay-Sachs and Sandhoff diseases. The preclinical data for AXO-AAV-GM2 in murine models showed dose-dependent increases in Hex A enzyme activity, reductions of GM2 gangliosides in the brain and prolonged survival rates.

Initial data with AXO-AAV-GM2 suggest stabilization of disease course, attainment of normal developmental milestones, and improvement in myelination on brain MRI.

Learn more at https://siogtx.com/

Dermavant
DMVT-504
Primary Focal Hyperhidrosis
Dermatology
Small Molecule
Phase 1

DMVT-504 is a combination of the muscarinic antagonist oxybutynin with the muscarinic agonist pilocarpine. DMVT-504 uses proprietary technology to control the release and dosing of pilocarpine with the goal of reducing the frequency and severity of dry mouth and potentially other side effects associated with oxybutynin.

Learn more at dermavant.com

Dermavant
Cerdulatinib
Atopic Dermatitis
Dermatology
Topical
Phase 1

Cerdulatinib is a topical dual janus kinase (JAK) and spleen tyrosine kinase (Syk) inhibitor. Dermavant is developing cerdulatinib as a topical therapy for a variety of dermatologic conditions. Dermavant believes that the profile of cerdulatinib is ideal for development in skin diseases where a growing body of evidence suggests that both JAK and Syk are important drivers of disease manifestation.

Learn more at dermavant.com

Lysovant
LSVT-1701
S. Aureus Bacteremia
Infectious Disease
Biologic
Phase 1
Sinovant
Vibegron
Overactive Bladder
Urology
Small Molecule
Phase 1
Affivant
AFM32
Solid Tumors
Oncology
Biologic
Preclinical
Cytovant
CVT-TCR-01
Oncologic Malignancies
Oncology
Cell Therapeutic
Preclinical

CVT-TCR-01 is a T cell receptor therapy being developed for the treatment of solid tumors. T cell receptor therapies utilize a patient’s own immune system to target tumor cells. In preparation for the therapy, a patient’s T cells are modified to express tumor-specific receptors that are then able to activate and mount an antitumor response. Through ex-vivo modification of a patient’s T cells, T cell receptor therapies can overcome natural T cell tolerance toward cancer cells and tumor-induced immunosuppression. Unlike CAR-T therapy, TCR-T therapy is designed to recognize intracellular antigens in addition to extracellular antigens, which may increase the number of tumors that can be successfully targeted.

Learn more at cytovant.com

Dermavant
DMVT-503
Acne Vulgaris
Dermatology
Small Molecule
Preclinical

DMVT-503 is an investigational drug candidate with a novel mechanism of action being developed for the topical treatment of acne.

Learn more at dermavant.com

People

Our leadership team includes industry veterans as well as exceptional leaders from outside of pharma.

Join Us
Filter By
Roivant Management
Vant Leadership
Board Members
Advisory Group
Roivant Management
Roivant Management
Vant Leadership
Board Members
Advisory Group
Filter By
Title
Vant
Sort By
Last Name
Vant
Full Name
Job Title
Company
News

Stay informed about the latest updates from across our family of companies.

Partners

Roivant has entered into a strategic alliance with Sumitomo Dainippon Pharma to deliver promising new medicines to patients. Other select partners are listed below.

Contact
NEW YORK
Roivant Sciences, Inc.
151 W 42nd Street, 15th Floor
New York, NY 10036
United States
BASEL
Roivant Sciences GmbH
Viaduktstrasse 8
4051 Basel
Switzerland
Inquiry Type
Investor Relations
Careers
Campus Recruiting
Other